effects of rituximab in patients with pemphigus vulgaris with oral lesions
Phase 2
Recruiting
- Conditions
- Pemphigus vulgaris lesion.Pemphigus vulgarisL10.0
- Registration Number
- IRCT20240604062002N1
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
People over 18 years old with pemphigus vulgaris with oral lesions
Patients who have not had a therapeutic response to corticosteroid administration
Patients for whom rituximab has been started
Exclusion Criteria
Pregnancy and breastfeeding
People who have coagulation problems
Patients with infection at the site of the lesion
Rituximab contraindications include hypersensitivity to it or its components
Having hepatitis B
Having cardiovascular diseases
Having malignant diseases
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of pemphigus vulgaris lesion. Timepoint: Before the study, on the 15th day, 33 months after the injection. Method of measurement: PVLSS: Pemphigus Vulgaris Lesion Severity Score.;Patient satisfaction. Timepoint: Before the study, on the 15th day, 33 months after the injection. Method of measurement: VAS: Visual analogue Scale.
- Secondary Outcome Measures
Name Time Method